This substudy aims to establish whether dalbavancin is non-inferior to standard of care with regard to 90 day all-cause mortality among people who inject drugs (PWID) with Staphylococcus aureus following documented clearance of bacteraemia.
SNAP Trial
Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia
Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.
PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.
Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia
